| Cash Flow | 2026-04-30 |
|---|---|
| Net loss for the period | -22,812,276 |
| Amortization | 11,453 |
| Financial income, net | 143,204 |
| Depreciation | 74,871 |
| Share-based compensation | 1,012,749 |
| Share of loss on equity investment | -171,126 |
| Change in fair value of the warrant liability | -265,818 |
| Unrealized gain on investment | 137,830 |
| Increase (decrease) in amounts receivable and prepaid expenses | -216,031 |
| Decrease in accounts payable | -1,109,266 |
| Increase in accrued expenses and other payables | 721,774 |
| Total cash flow from operating activities | -22,692,452 |
| Purchase of equipment | 127,049 |
| Purchase of short-term investments | 15,781,000 |
| Proceeds from short-term investments | 7,372,473 |
| Equity investment in bc therapeutics | 260,000 |
| Total cash flow from investing activities | -8,795,576 |
| Proceeds from the issuance of shares, net of issuance costs | 27,874,441 |
| Total cash flow from financing activities | 27,874,441 |
| Increase (decrease) in cash and cash equivalents | -3,613,587 |
| Cash and cash equivalents at beginning of the period | 10,493,808 |
| Cash and cash equivalents at end of the period | 6,880,221 |
BriaCell Therapeutics Corp. (BCTXL)
BriaCell Therapeutics Corp. (BCTXL)